News

Virginia Catalyst Awards $3.2 Million in Grants to Support Life Sciences in the Commonwealth

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These projects were awarded in Grant Round 17.

“The Catalyst works to help industry partners and academic investigators to raise follow-on funding” said Mike Grisham, CEO of Virginia Catalyst. Through this 17th round of funding, Virginia Catalyst has awarded 69 grants totaling over $36 million, resulting in over $54 million in matching funds and over $700 million in follow-on funding to date.

The Virginia Catalyst in now accepting Letters of Intent for Grant Round 18, until March 14th.
For more information visit: https://www.VirginiaCatalyst.org/apply.html

Grant Round 17 project awardees:

Project: Adenosine A2B receptor blockade for the treatment of Clostridium difficile infection (CDI) •Company: Adovate, LLC (Charlottesville, VA)
•University collaborators: University of Virginia and Virginia Tech
•Funding amount: $800,000

Project: Anti-bioflim enzyme (ABE) as a novel, non-toxic solution that overcomes antimicrobial resistance to protect human health from farm to fork
• Company: Lytos Technologies, LLC (Charlottesville, VA)
•University collaborators: University of Virginia and Virginia Tech
•Funding amount: $800,000

Project: Orthopaedic Surgical Site Infection Prevention via an Antibiotic Releasing Click Hydrogel
•Company: Pascal Medical Corporation (Richmond, VA)
•University collaborators: Virginia Commonwealth University and George Mason University
•Funding amount: $800,000

Project: Investigational New Drug Enabling Studies of STX2310
•Company: S1P Therapeutics Inc. (Blacksburg, VA)
•University collaborators: Virginia Tech and University of Virginia
•Funding amount: $800,000

 

Recent News

04/02/2025

VCU startup wins $800k grant to propel its infection-fighting surgical gel

With an innovation that could advance brain and spinal surgeries, a Virginia Commonwealth University startup has received an $800,000 state grant to support development of its infection-fighting gel. Pascal Medical Corp. is one of four grant recipients to receive awards from Virginia Catalyst, a nonprofit created by the General Assembly and funded by the state’s general

04/02/2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application

04/02/2025

Charlottesville Angel Network Celebrates 10 Years, Surpasses $20 Million in Investments

The Charlottesville Angel Network (CAN), a group of accredited investors dedicated to supporting early-stage ventures, proudly marks its 10th anniversary this month. Since its inception, CAN angel investor members have invested more than $20 million in nearly 80 startups, fostering innovation both locally and beyond. Reflecting on a decade of achievements, CAN has realized returns